Faerch Mia, Christensen Jane H, Corydon Thomas J, Kamperis Konstantinos, de Zegher Francis, Gregersen Niels, Robertson Gary L, Rittig Søren
Department of Pediatrics, Aarhus University Hospital, Skejby, Aarhus, Denmark.
Clin Endocrinol (Oxf). 2008 Mar;68(3):395-403. doi: 10.1111/j.1365-2265.2007.03054.x. Epub 2007 Oct 17.
To identify the molecular basis and clinical characteristics of X-linked congenital nephrogenic diabetes insipidus (CNDI) presenting with an unusual phenotype characterized by partial resistance to AVP.
The proband was admitted at the age of 4 years with a history of polydipsia and polyuria since infancy. Initial clinical testing confirmed a diagnosis of diabetes insipidus (DI). Urine osmolarity rose during fluid deprivation and after 20 microg of intranasal desmopressin [1-deamino-8-D-arginine-vasopressin (dDAVP)]. A similar DI phenotype was found in his brother.
The coding regions of the AVP gene and the AVP receptor 2 (AVPR2) genes were sequenced in two affected and three unaffected family members. Clinical studies included a fluid deprivation test, intranasal dDAVP challenge, infusion of graded doses of dDAVP and AVP, and measurements of 24-h urine output before and at the end of a 7-day therapeutic trial of intranasal dDAVP.
A novel missense mutation (1454C > A) in exon 3 of the AVPR2 gene predicting a Ser329Arg substitution was identified in the X-chromosome of the two affected brothers and in one of the X-chromosomes in the mother. The AVPR2 gene was normal in two unaffected siblings. Under basal conditions, the 24-h urine volumes of the two affected boys were 5.5 l (229 ml/kg) and 3.5 l (192 ml/kg), the urine osmolalities were 78 and 90 mosm/kg, and plasma AVP 13.5 and 19.0 pg/ml. Urine osmolalities increased to 573 and 720 mosm/kg while plasma AVP levels were practically unchanged, 13.6 and 8.8 pg/ml, during fluid deprivation. Infusion of AVP resulted in urine osmolalities of 523 and 623 mosm/kg at plasma AVP levels of 58 and 42 pg/ml. Infusion of dDAVP had a similar effect, while treatment with standard doses of intranasal dDAVP had no effect on urine output.
The affected members of this Belgian kindred have CNDI with partial resistance to AVP caused by a mutation in the AVPR2 gene that differs from any of the six mutations reported previously to produce this phenotype. Because the resistance to AVP is partial, this form of CNDI can be difficult to distinguish by indirect diagnostic tests from partial pituitary and dipsogenic DI.
确定以对血管加压素(AVP)有部分抵抗为特征的不寻常表型的X连锁先天性肾性尿崩症(CNDI)的分子基础和临床特征。
先证者4岁入院,自婴儿期起有多饮多尿史。初步临床检查确诊为尿崩症(DI)。禁水期间及鼻内给予20微克去氨加压素[1-去氨基-8-D-精氨酸血管加压素(dDAVP)]后尿渗透压升高。在其兄弟中发现了类似的DI表型。
对两名患病和三名未患病家庭成员的AVP基因和AVP受体2(AVPR2)基因的编码区进行测序。临床研究包括禁水试验、鼻内dDAVP激发试验、不同剂量dDAVP和AVP输注,以及在鼻内dDAVP 7天治疗试验前后测量24小时尿量。
在两名患病兄弟的X染色体以及母亲的一条X染色体上,发现AVPR2基因第3外显子有一个新的错义突变(1454C>A),预测丝氨酸329被精氨酸取代。两名未患病的兄弟姐妹的AVPR2基因正常。在基础条件下,两名患病男孩的24小时尿量分别为5.5升(229毫升/千克)和3.5升(192毫升/千克),尿渗透压分别为78和90毫渗摩尔/千克,血浆AVP分别为13.5和19.0皮克/毫升。禁水期间,尿渗透压分别升至573和720毫渗摩尔/千克,而血浆AVP水平实际未变,分别为13.6和8.8皮克/毫升。输注AVP导致血浆AVP水平分别为58和42皮克/毫升时尿渗透压为523和623毫渗摩尔/千克。输注dDAVP有类似效果,而标准剂量鼻内dDAVP治疗对尿量无影响。
这个比利时家族的患病成员患有CNDI,对AVP有部分抵抗,是由AVPR2基因突变引起的,该突变不同于先前报道的产生这种表型的六个突变中的任何一个。由于对AVP的抵抗是部分性的,这种形式的CNDI通过间接诊断测试可能难以与部分垂体性和致渴性DI区分开来。